YH-001 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YH-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YH-001 overview

YH-001 is under development for the treatment of advanced solid tumors, melanoma, gastroesophageal (GE) junction carcinomas, advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, chondrosarcoma, leiomyosarcoma, dedifferentiated liposarcoma and hepatocellular carcinoma (HCC). The drug candidate is a tumor immune checkpoint antibody. It acts by targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). It is developed based on hybridoma technology. It is administered through intravenous route.

Eucure (Beijing) Biopharma overview

Eucure (Beijing) Biopharma is a biotechnology company that discovery and development of innovative immuno-oncology targeted antibodies. The company is headquartered China.

For a complete picture of YH-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.